Andersen, Johanna B., Sharmin, Sifat, Lefort, Mathilde, Koch-Henriksen, Nils, Sellebjerg, Finn, Sørensen, Per Soelberg, Hilt Christensen, Claudia C., Rasmussen, Peter V., Jensen, Michael B., Frederiksen, Jette L., Bramow, Stephan, Mathiesen, Henrik K., Schreiber, Karen I., Horakova, Dana, Havrdova, Eva K., Alroughani, Read, Izquierdo, Guillermo, Eichau, Sara, Ozakbas, Serkan, Patti, Francesco, Onofrj, M, Lugaresi, A, Terzi, M, Grammond, P, Grand Maison, F, Yamout, B, Prat, A, Girard, M, Duquette, P, Boz, C, Trojano, M, McCombe, P, Slee, M, Lechner-Scott, Jenette, Turkoglu, R, Sola, P, Ferraro, D, Granella, F, Shaygannejad, V, Prevost, J, Skibina, O, Solaro, C, Karabudak, R, Wijmeersch, BV, Csepany, T, Spitaleri, D, Vucic, S, Casey, R, Debouverie, M, Edan, G, Ciron, J, Ruet, A, Sèze, JD, Maillart, E, Zephir, H, Labauge, P, Defer, G, Lebrun, C, Moreau, T, Berger, E, Clavelou, P, Pelletier, J, Stankoff, B, Gout, O, Thouvenot, E, Heinzlef, O, Al-Khedr, A, Bourre, B, Casez, O, Cabre, P, Montcuquet, A, Wahab, A, Camdessanché, JP, Marousset, A, Patry, I, Hankiewicz, K, Pottier, C, Maubeuge, N, Labeyrie, C, Nifle, C, Leray, E, Laplaud, DA, Butzkueven, H, Kalincik, T, Vukusic, S, Magyari, M. Elsevier; 2021. The effectiveness of natalizumab vs fingolimod - A comparison of international registry studies.

Kalincik, Tomas, Sharmin, Sifat, Grigg, Andrew, Torkildsen, Øivind, Bo, Lars, Lehmann, Anne Kristine, Havrdova, Eva Kubala, Krasulova, Eva, Trnený, Marek, Kozak, Tomas, van der Walt, Anneke, Butzkueven, Helmut, Roos, Izanne, McCombe, Pamela, Skibina, O, Lechner-Scott, Jeanette, Willekens, B, Cartechini, E, Ozakbas, S, Alroughani, R, Kuhle, J, Patti, F, Duquette, P, Freedman, Mark S., Lugaresi, A, Khoury, SJ, Slee, M, Turkoglu, R, Hodgkinson, S, John, N, Maimone, D, Sa, MJ, van Pesch, V, Gerlach, O, Atkins, Harold, Laureys, G, Van Hijfte, L, Karabudak, R, Spitaleri, D, Csepany, T, Gouider, R, Castillo-Triviño, T, Taylor, B, Sharrack, B, Snowden, JA, Burman, Joachim, MSBase Study Group Collaborators,, MSBase Study Group Authors,, Mrabet, S, Garber, J, Sanchez-Menoyo, JL, Aguera-Morales, E, Blanco, Y, Al-Asmi, A, Weinstock-Guttman, B, Fragoso, Y, Massey, Jennifer, de Gans, K, Kermode, A, MSBase Study Group,, Sutton, Ian, Withers, Barbara, Macdonell, Richard. Amercian Medical Association; 2023. Comparative Effectiveness of Autologous Hematopoietic Stem Cell Transplant vs Fingolimod, Natalizumab, and Ocrelizumab in Highly Active Relapsing-Remitting Multiple Sclerosis.

Li, Ying, Saul, Alice, Eichau, Sara, Onofrj, Marco, Ozakbas, Serkan, Horakova, Dana, Havrdova, Eva Kubala, Grand'Maison, Francois, Alroughani, Raed, Gerlach, Oliver, Amato, Maria Pia, Altintas, Ayse, Taylor, Bruce, Girard, M, Duquette, P, Blanco, Y, Ramo-Tello, C, Laureys, G, Kalincik, T, Khoury, SJ, Shaygannejad, V, Etemadifar, M, Singhal, B, Ponsonby, Anne-Louise, Mrabet, S, Foschi, M, Habek, M, John, N, Hughes, S, McCombe, P, Ampapa, R, van der Walt, A, Butzkueven, H, de Gans, K, Simpson-Yap, Steve, McGuigan, C, Oreja-Guevara, C, Sa, MJ, Petersen, T, Al-Harbi, T, Sempere, AP, Van Wijmeersch, B, Grigoriadis, N, Prevost, J, Gray, O, Blizzard, Leigh, Castillo-Trivino, T, Macdonell, R, Lugaresi, A, Sajedi, SA, van der Mei, I, Broadley, Simon, Lechner-Scott, Jeannette, Karabudak, Rana, Patti, Francesco. Springer; 2024. Examining the environmental risk factors of progressive-onset and relapsing-onset multiple sclerosis: recruitment challenges, potential bias, and statistical strategies.